AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Medullary Thyroid Cancer - Pipeline Insight, 2019 - ResearchAndMarkets.com

February 15, 2019

DUBLIN--(BUSINESS WIRE)--Feb 15, 2019--The “Medullary Thyroid Cancer - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Medullary Thyroid Cancer - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Medullary Thyroid Cancer development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

The report provides a snapshot of the pipeline development for Medullary Thyroid Cancer The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Medullary Thyroid Cancer The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Medullary Thyroid Cancer The report also covers the dormant and discontinued pipeline projects related to Medullary Thyroid Cancer

Companies Mentioned

AbbVie Inc. Advenchen Laboratories Bayer AG Boehringer Ingelheim GmbH Celgene Corporation Hutchison MediPharma Limited Immunomedics Nerviano Medical Sciences S.r.l. Novartis AG

Topics Covered

1. Report Introduction

2. Medullary Thyroid Cancer Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Medullary Thyroid Cancer

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/p32hxd/medullary_thyroid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190215005340/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Thyroid Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/15/2019 10:52 AM/DISC: 02/15/2019 10:52 AM

http://www.businesswire.com/news/home/20190215005340/en